Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Against the backdrop of poor sales of the company’s COVID-19 shot Spikevax and its RSV prophylactic mRESVIA, Moderna is “accelerating and expanding” its prior cost efficiency and ...

Moderna's RSV vaccine earned approval last May, but sales haven't gotten off the ground yet. The biotech company expects to lose money again in 2025, but operating expenses are declining.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of its ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said it ...

The 2024 winter virus season has seen slower respiratory vaccine demand, including for COVID and RSV, which most severely impact children and elderly adults. Moderna launched its RSV vaccine last ...